Amneal Pharmaceuticals is a U.S.-based diversified biopharmaceutical company that develops, manufactures, markets, and distributes essential medicines across generics, injectables, biosimilars, branded specialty drugs, and government-focused distribution. Its business is organized into three reportable segments: Affordable Medicines, Specialty, and AvKARE. The company operates mainly in the United States, India, and Ireland, with manufacturing and commercial activities spanning both developed and international markets. Amneal’s model combines high-volume generic and injectable products with a branded specialty portfolio and a federal-government distribution channel, giving it multiple revenue streams but also exposing it to pricing pressure, regulation, and customer concentration.
15,0 %
36,9 %
2,4 %
+8,0 %
2.17
1.48
| % | |
|---|---|
| Affordable Medicines | 65% Retail generics, sterile injectables, and biosimilars sold primarily in the U.S. market. |
| Specialty Pharmaceuticals | 20% Branded medicines focused mainly on central nervous system and endocrine disorders. |
| AvKARE Distribution | 15% Pharmaceutical and medical product distribution to U.S. federal, retail, and institutional customers. |
Amneal sells mainly into the U.S. pharmaceutical supply chain, where wholesalers, large chain retailers, mail-order...
Buy generics and other high-volume medicines for broad retail distribution and price-sensitive demand.
Purchase injectables, biosimilars, and selected generics to secure supply and pricing for member networks.
Buy sterile injectables and other essential medicines where continuity of supply and compliance matter.
Influence and prescribe branded specialty products in CNS and endocrine therapy areas.
Buy pharmaceuticals and medical products through AvKARE for defense, veterans, and other institutional needs.
Amneal operates principally in the United States, India, and Ireland, reflecting a mix of U.S...
Amneal’s strategy is to broaden its portfolio across generics, injectables, biosimilars, specialty branded products,...
Fresh launches help offset price erosion in mature generics and support revenue growth.
Capacity, quality, and reliability are critical in generics, injectables, and biosimilars where shortages or delays can lose customers.
A broader mix across affordable medicines, specialty, and government distribution reduces dependence on any one product category.
AvKARE provides access to large institutional buyers but requires disciplined contracting and procurement management.
Amneal faces the typical risks of a generic and specialty pharmaceutical company: regulatory approval delays, patent...
A small number of wholesalers and distributors account for a very large share of sales, so lost volume or pricing pressure from one customer can materially affect revenue.
The company depends on FDA and DEA approvals, inspections, and quotas to launch products and operate controlled-substance businesses.
Generic products are commoditized and competitors can quickly pressure price and share after launch or patent expiry.
Branded competitors may challenge generic launches through patent infringement or related legal actions.
AvKARE depends on federal contracting and agency purchasing, which can be delayed by shutdowns or slower payment cycles.
AMGN · Biological Products, (No Diagnostic Substances)
AMPH · Pharmaceutical Preparations
AMLX · Pharmaceutical Preparations
COR · Wholesale-Drugs, Proprietaries & Druggists' Sundries
Cencora is a pharmaceutical sourcing and distribution company that sits between drug manufacturers and healthcare providers, moving branded, specialty,…
ANIP · Pharmaceutical Preparations
ANI Pharmaceuticals is a U.S.-based biopharmaceutical company that develops, manufactures, and commercializes prescription therapeutics across Rare Disease, Generics, and Brands.
AMWL · Services-Business Services, NEC
American Well Corp, which operates as Amwell, builds digital care software and services for healthcare organizations.
: 11/08/2026